References
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329:977–86
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
- American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27(Suppl 1):S15–S35
- Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999;22(Suppl 2):B109–B113
- Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003;25:1541–77 [discussion]
- Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000;23:157–62
- Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. [U.S. Study Group of Insulin Glargine in Type 1 Diabetes]. Diabetes Care 2000;23:639–43
- Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. [HOE 901/3002 Study Group]. Diabetes Care 2000;23: 1130–6
- Rosenstock J, Schwartz SL, Clark Jr CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631–6
- Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26: 3080–6
- Moulton B. Random group effects and the precision of regression estimates. J Econometrics 1986;32:385–97
- Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, over-dispersed Poisson, and negative binomial models. Psychol Bull 1995;118:392–404
- Long J. Regression models for categorical and limited dependent variables. Thousand Oaks (CA): Sage Publications; 1997
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45: 613–9
- Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. J Am Med Assoc 1998;280:1490–6
- Gilmer TP, O’Connor PJ, Manning WG, et al. The cost to health plans of poor glycemic control. Diabetes Care 1997;20:1847–53
- Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. J Am Med Assoc 2001;285:182–9
- Menzin J, Langley-Hawthorne C, Friedman M, et al. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001;24:51–5
- Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000;23:390–404
- Yki-Jarvinen H, Haring H, Johnson E, et al. The relationship between glycemic control and hypoglycemia using insulin glargine versus NPH insulin: a meta-regression analysis in type 2 diabetes. Diabetes 2003;52\(Suppl 1):A149
- Collins FM. Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings. Am J Manag Care 2002;8:S460–S471
- Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J Am Med Assoc 2002;287:360–72
- Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27: 17–20
- Wyne KL, Bell DS, Braunstein S, et al. Trends in management of type 2 diabetes: role of thiazolidinediones. The Endocrinologist 2003;13:S1–S21